Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Long-Term Deferred Tax (2024)

Coeptis Therapeutics Holdings (COEP) has 1 years of Long-Term Deferred Tax data on record, last reported at $18.8 million in Q4 2022.

  • For Q4 2022, Long-Term Deferred Tax changed N/A year-over-year to $18.8 million; the TTM value through Dec 2022 reached $18.8 million, changed N/A, while the annual FY2022 figure was $18.8 million, N/A changed from the prior year.
  • Long-Term Deferred Tax reached $18.8 million in Q4 2022 per COEP's latest filing.
  • Across five years, Long-Term Deferred Tax topped out at $18.8 million in Q4 2022 and bottomed at $18.8 million in Q4 2022.